Assessment of Clinical Features in HIV-Infected Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention in China

Overview

Journal J Interv Cardiol

Publisher Wiley

Specialty Cardiology & Vascular Diseases

Date 2022 Jul 18

PMID 35847237

Authors

Ying Liu

Yongfu Chen

Yiwei Hao

Jing Xiao

Bei Li

Leidan Zhang

Junyan Han

Hongxin Zhao

Affiliations

Soon will be listed here.

Abstract

Objectives: We aimed to compare coronary risk factors, burden of coronary artery disease (CAD), and 1-year prognosis of people living with HIV (PLWH) and HIV-negative controls who underwent percutaneous coronary intervention (PCI) for acute coronary syndromes (ACSs).

Background: Cardiovascular disease is drawing more and more attention in PLWH since effective antiretroviral therapy (ART) has been available. Clinical characteristics and outcomes of PLWH undergoing PCI for ACS in China remain unknown.

Methods: We compared demographic characteristics, angiographic features, and 1-year outcomes of 48 PLWH versus 48 HIV-negative controls matched for age (±2 years), sex, diabetes mellitus, and year of PCI (±2 years) in Beijing Ditan Hospital, Capital Medical University from January 2008 to November 2020.

Results: In PLWH (mean age: 53.6 ± 10.6 years, 95.8% male, and 79.2% on ART), high-density lipoprotein cholesterol was lower than in HIV-negative controls; however, the statin use was more common, the incidence of hypertension was lower, and low-density lipoprotein cholesterol, and the body mass index were significantly lower than in controls. Two groups had a similar extent of coronary atherosclerosis as measured by the presence of multivessel diseases and the median Gensini score; however, lesions of PLWH were longer and were more likely to locate at the proximal segment of the coronary artery. In addition, the risk of major adverse cardiac and cerebrovascular events at 1 year was similar in both groups.

Conclusion: PLWH undergoing PCI displayed similar CAD burden and 1-year prognosis compared with HIV-negative patients. Early detection of cardiovascular risk factors and appropriate secondary prevention of CAD in PLWH might alleviate the risk of severe adverse cardiovascular events.

Citing Articles

Cardiovascular Risk Factors, Angiographical Features and Short-Term Prognosis of Acute Coronary Syndrome in People Living with Human Immunodeficiency Virus: Results of a Retrospective Observational Multicentric Romanian Study.

Bajdechi M, Gurghean A, Bataila V, Scafa-Udriste A, Radoi R, Oprea A Diagnostics (Basel). 2023; 13(9).

PMID: 37174918 PMC: 10177561. DOI: 10.3390/diagnostics13091526.

References

Eagle K, Lim M, Dabbous O, Pieper K, Goldberg R, Van de Werf F . A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA. 2004; 291(22):2727-33. DOI: 10.1001/jama.291.22.2727. View

Theodoropoulos K, Mennuni M, Sartori S, Meelu O, Yu J, Baber U . Quantitative angiographic characterisation of coronary artery disease in patients with human immunodeficiency virus (HIV) infection undergoing percutaneous coronary intervention. EuroIntervention. 2016; 12(14):1757-1765. DOI: 10.4244/EIJ-D-15-00409. View

. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. Lancet HIV. 2017; 4(8):e349-e356. PMC: 5555438. DOI: 10.1016/S2352-3018(17)30066-8. View

Bernelli C, Danzi G, Cerrato E, Pierini S, Ornaghi M, Botta L . Cardiovascular Events Recurrence and Coronary Artery Disease in HIV Patients: The Price We Have to Pay for the Chronicization of the Disease. Can J Cardiol. 2019; 36(1):127-134. DOI: 10.1016/j.cjca.2019.07.636. View

Freiberg M, Chang C, Kuller L, Skanderson M, Lowy E, Kraemer K . HIV infection and the risk of acute myocardial infarction. JAMA Intern Med. 2013; 173(8):614-22. PMC: 4766798. DOI: 10.1001/jamainternmed.2013.3728. View

Escaut L, Monsuez J, Chironi G, Merad M, Teicher E, Smadja D . Coronary artery disease in HIV infected patients. Intensive Care Med. 2003; 29(6):969-973. DOI: 10.1007/s00134-003-1740-0. View

Boccara F, Teiger E, Cohen A, Ederhy S, Janower S, Odi G . Percutaneous coronary intervention in HIV infected patients: immediate results and long term prognosis. Heart. 2006; 92(4):543-4. PMC: 1860867. DOI: 10.1136/hrt.2005.068445. View

Boccara F, Mary-Krause M, Teiger E, Lang S, Lim P, Wahbi K . Acute coronary syndrome in human immunodeficiency virus-infected patients: characteristics and 1 year prognosis. Eur Heart J. 2010; 32(1):41-50. DOI: 10.1093/eurheartj/ehq372. View

Ingle S, May M, Gill M, Mugavero M, Lewden C, Abgrall S . Impact of risk factors for specific causes of death in the first and subsequent years of antiretroviral therapy among HIV-infected patients. Clin Infect Dis. 2014; 59(2):287-97. PMC: 4073781. DOI: 10.1093/cid/ciu261. View

10.

Lorgis L, Cottenet J, Molins G, Benzenine E, Zeller M, Aube H . Outcomes after acute myocardial infarction in HIV-infected patients: analysis of data from a French nationwide hospital medical information database. Circulation. 2013; 127(17):1767-74. DOI: 10.1161/CIRCULATIONAHA.113.001874. View

11.

Marcus J, Leyden W, Alexeeff S, Anderson A, Hechter R, Hu H . Comparison of Overall and Comorbidity-Free Life Expectancy Between Insured Adults With and Without HIV Infection, 2000-2016. JAMA Netw Open. 2020; 3(6):e207954. PMC: 7296391. DOI: 10.1001/jamanetworkopen.2020.7954. View

12.

Triant V, Lee H, Hadigan C, Grinspoon S . Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab. 2007; 92(7):2506-12. PMC: 2763385. DOI: 10.1210/jc.2006-2190. View

13.

Matetzky S, Domingo M, Kar S, Noc M, Shah P, Kaul S . Acute myocardial infarction in human immunodeficiency virus-infected patients. Arch Intern Med. 2003; 163(4):457-60. DOI: 10.1001/archinte.163.4.457. View

14.

Karami M, Peters E, Lagrand W, Houterman S, den Uil C, Engstrom A . Outcome and Predictors for Mortality in Patients with Cardiogenic Shock: A Dutch Nationwide Registry-Based Study of 75,407 Patients with Acute Coronary Syndrome Treated by PCI. J Clin Med. 2021; 10(10). PMC: 8151113. DOI: 10.3390/jcm10102047. View

15.

Okeke N, Alenezi F, Bloomfield G, Dunning A, Clement M, Shah S . Determinants of Left Ventricular Hypertrophy and Diastolic Dysfunction in an HIV Clinical Cohort. J Card Fail. 2018; 24(8):496-503. PMC: 6231907. DOI: 10.1016/j.cardfail.2018.06.003. View

16.

Ren X, Trilesskaya M, Kwan D, Nguyen K, Shaw R, Hui P . Comparison of outcomes using bare metal versus drug-eluting stents in coronary artery disease patients with and without human immunodeficiency virus infection. Am J Cardiol. 2009; 104(2):216-22. DOI: 10.1016/j.amjcard.2009.03.036. View

17.

Thienemann F, Sliwa K, Rockstroh J . HIV and the heart: the impact of antiretroviral therapy: a global perspective. Eur Heart J. 2013; 34(46):3538-46. DOI: 10.1093/eurheartj/eht388. View

18.

Boccara F, Lang S, Meuleman C, Ederhy S, Mary-Krause M, Costagliola D . HIV and coronary heart disease: time for a better understanding. J Am Coll Cardiol. 2013; 61(5):511-23. DOI: 10.1016/j.jacc.2012.06.063. View

19.

DAscenzo F, Cerrato E, Biondi-Zoccai G, Moretti C, Omede P, Sciuto F . Acute coronary syndromes in human immunodeficiency virus patients: a meta-analysis investigating adverse event rates and the role of antiretroviral therapy. Eur Heart J. 2011; 33(7):875-80. PMC: 3345544. DOI: 10.1093/eurheartj/ehr456. View

20.

Stein J, Hsue P . Inflammation, immune activation, and CVD risk in individuals with HIV infection. JAMA. 2012; 308(4):405-6. DOI: 10.1001/jama.2012.8488. View